OEM overview
Private-label dissolvable microneedle patch development using Acetyl Hexapeptide-8 for appearance-focused wrinkle-care concepts. Each program is reviewed for cosmetic category, technical feasibility, target-market rules and manufacturability before samples begin.
Formula and active options
Potential directions include Acetyl Hexapeptide-8, hyaluronic acid and compatible moisturizing ingredients. Final composition, active level, compatibility and claims depend on the agreed specification, stability strategy and destination market.
Cosmetic positioning
Programs may be positioned for temporary smoothing, hydration and improvement in the appearance of expression lines. We avoid medical or drug claims unless the customer establishes a separate, appropriately authorized development pathway.
Customization options
OEM / private-label workflow
- Submit product brief, target market, volume and timing.
- Confirm technical assumptions, sample scope and commercial pathway.
- Develop or adapt formula and patch geometry.
- Evaluate samples against agreed appearance, handling and dissolution criteria.
- Align packaging, pilot plan, specifications and production documents.
Appearance-focused wrinkle-care positioning
Acetyl Hexapeptide-8 is commonly considered for cosmetic expression-line concepts. Product copy should describe visible appearance, hydration and smoothing rather than presenting the patch as an injection substitute or claiming a drug-like mechanism.
Development questions
- Which facial area and patch contour are planned?
- What content, polymer system and drying exposure are technically feasible?
- How will distribution within the array and finished-product stability be assessed?
- Which claims can the brand substantiate in its destination market?
For broader ingredient positioning, see our palmitoyl peptide and multi-peptide programs.
Questions buyers ask before the next step
The following answers convert this page into a decision-ready reference rather than a general marketing summary. Each answer states the conclusion first and then names the variables that can change it. Numerical values such as MOQ, lead time, active content, dimensions, shelf life and price are not presented as universal facts when they depend on an unapproved project specification. This makes the page easier for both human buyers and AI systems to quote accurately: confirmed company or process information remains separate from product-specific assumptions, while cosmetic, medical and jurisdictional boundaries stay visible. For a live project, use these answers to prepare the brief and request the supporting specification, test or contractual record. Mark unresolved inputs as open actions with an owner and due date, then update the controlled project version after evidence is reviewed.
Is Acetyl Hexapeptide-8 HYTANBIO Microneedle Patches OEM a ready-stock product?
This page describes a potential custom cosmetic development direction, not guaranteed ready inventory. Formula, active level, array geometry, backing, packaging, MOQ, lead time, evidence and target-market acceptability must be confirmed for the buyer’s approved brief.
Which specifications should be confirmed before sampling?
Confirm ingredient identity and target content basis, matrix and patch dimensions, needle geometry, application area, backing and pouch system, appearance and handling criteria, dissolution method, storage conditions, desired shelf life and claims direction. Record the sample version so feedback is traceable.
Which claims can the finished patch use?
Claims must remain consistent with the product category and be supported for the finished product as presented and used. Ingredient studies do not automatically substantiate the patch. Avoid treatment, disease, structural or drug-delivery claims unless a separate qualified regulatory pathway has been established.
Content review: Last reviewed September 29, 2026. Material changes to formula, claims, manufacturing scope or target market require a fresh review.